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Polyclonal antibodies (AS 232-266) have been raised against the 232-266 amino acid sequence of the mouse hsp 84. This sequence posseses 54% 
acidic residues. AS 232-266 react with both the denatured and the free native murine hsp 84, but not with the bound hsp 84 present in the 
untransformed glucocorticoid receptor complexes (GR). Both AS 232-266 and peptide 232-266 were shown to decrease [‘Hldexamethasone binding 
by GR. Moreover synthetic peptide 232-266, when added to 7 nm untransformed GR, convert them into 5 nm hsp 84-free GR. Taken together 
these data suggest hat the acidic 232-266 sequence of hsp 84 is involved in the stabilization of the hsp 84GR interaction, which is known to result 
in 7 nm complex formation and in GR ligand binding activity improvement. Both peptide 232-266 and AS 232-266 destabilize this interaction. 
Glucocorticoid receptor; Heat shock protein, 90 kDa 
1. INTRODUCTION 2. MATERIALS AND METHODS 
When prepared in buffers of low ionic strength gluco- 
corticoid receptors (GR) exist as heteromeric omplexes 
that do not bind DNA [I]. The core of these untrans- 
formed complexes consists of one steroid subunit and 
a dimer of hsp 90 [2,3], to which other heat shock pro- 
teins, including hsp 70 and hsp 56 are less tightly associ- 
ated [4,5]. Hormone binding induces a temperature-de- 
pendent association of GR from hsp 90 and their con- 
version to the DNA-binding form [6]. Reassociation of 
transformed GR with hsp 90 is accompanied by func- 
tional reconstitution of the untransformed state of the 
receptor [7]. The recent demonstration that hsp 90 is 
necessary for the high affinity steroid binding activity 
of GR [8] and that hsp 90-GR complexes exist in intact 
cells [9] still reinforce interest for the hsp 90-GR inter- 
action. Whereas several regions involved in the forma- 
tion of stable complexes with hsp 90 have been localized 
in the sequence of GR [l&15] and other steroid 
hormone receptors [ 16181, the corresponding regions 
of hsp 90 still remain unidentified. One possible candi- 
date is a highly charged sequence present in all eukar- 
yotic hsp 90 [19]. 
2.1. Synthesis of peptide and preparation of antibodies 
A 36-mer peptide (corresponding to the mouse and rat hsp 90 
sequences in Fig. 1 plus an additional N-terminal cysteine for cou- 
pling) was synthesized by the Merrifield solid-phase method [20] and 
purified by gel filtration on Biogel P4 (Bio-Rad, France) and reversed- 
phase HPLC on 5 pm Nucleosil C8 (Machery Nagel, Germany). 
Covalent coupling to bovine serum albumin (BSA) was performed 
using succinimidyl 4-N-maleimidomethyl cyclohexane carboxylate 
[21]. The peptide to BSA ratio in the conjugate was 18:l. Two New 
Zealand rabbits were immunized [22] and anti hsp 90 antisera were 
tested by Western blotting. Positive antisera were fractionated by 33% 
(w/v) ammonium sulfate precipitation, redissolved in phosphate-buff- 
ered saline (10 mM sodium phosphate, 150 mM sodium chloride, pH 
7.0) and submitted to gel filtration on an Ultrogel ACA 202 column 
(IBF, France) equilibrated in the same buffer. 
2.2. Cytosol preparation and steroid binding assay 
Cytosol of rat and mouse liver was prepared as previously described 
[23] in buffer A: 20 mM TES (N-tris-hydroxymethyl-methyl-2-ami- 
noethane sulfonic acid) pH 7.4, 1 mM dithiothreitol, 1 mM PMSF 
(phenylmethane sulfonic fluoride), IO mM sodium molybdate and 
10% glycerol. Steroid binding was performed with [6,7-‘HIdexam- 
ethasone (40 Ci/mmol, NEN, Boston, MA) using a dextran-coated 
charcoal assay [23]. Non-specific binding was determined in parallel 
samples in the presence of a l,OOO-fold molar excess of unlabelled 
dexamethasone. 
We demonstrate here that both a synthetic peptide 
chosen in this sequence and a polyclonal antibody 
raised against this peptide, are able to stabilize hsp 90- 
GR complexes. 
2.3. Hsp 90 purification 
Hsp 90 from rat or mouse liver cytosol was purified using protamine 
sulfate precipitation followed by ion-exchange chromatography on a 
Mono Q HR 5/5 column (Pharmacia Biotechnology) and high-per- 
formance size-exclusion chromatography on a TSK G4000 SW col- 
umn (Tbarka, in preparation). The purified protein was labelled with 
‘*‘I using the Bolton and Hunter procedure [24]. 
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2.4. Gel electrophoresis and immunoblotting 
SDS-PAGE was performed on 7.5% slab gels under reducing condi- 
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tions [25]. After electrotransfer to a nitrocellulose sheet, immunologi- 
cal revelation was performed [26] using anti-hsp 90 antibodies (mono- 
clonal antibody AC 88 was a kind gift of Dr. 0. Toft) at a 1:lOOO to 
1:5000 final dilution. Peroxidase-conjugated anti-mouse or anti-rabbit 
IgG antibodies were used for detection. 
3. RESULTS 
3.1. An antibody specijk of the free hsp 90 
A very charged peptide, mapping from residue 232 to 
residue 266 of mouse hsp 90/3 sequence [27,28], was 
chosen using prediction of antigenic regions of proteins 
and synthesized (Fig. 1). This peptide belongs to an 
acidic domain of eucaryotic hsp 90 in which charges are 
roughly conserved among species, despite unperfect se- 
quence homology [19,27-301. In human and mice two 
hsp 90 isoforms, hsp 90a and hsp 90/3, encoded by 
separate genes have been described [28,29]. Both exist 
as homodimers [31] and are present in the untrans- 
formed GR complexes [32]. Peptide 232-266 was used 
to raise antibodies in rabbits and a positive antiserum, 
AS 232-266, was obtained. AS 232-266 recognized 
murine cytosolic hsp 90 in Western blots at a dilution 
greater than 1:8,000 (Fig. 2). A control using AC 88, a 
monoclonal antibody recognizing all eukaryotic hsp 90 
[33], is also shown. AS 232-266 binding appeared spe- 
cific, since it was abolished by preincubation with pep- 
tide 232-266 and not with an unrelated peptide. Moreo- 
ver AS 232-266 crossreacts with both hsp 90 isoforms 
and with hsp 90 from other species, including chick, rat 
and human (data not shown). Interestingly AS 232-266 
recognizes hsp 90 in its native free form (Fig. 3A): ‘251- 
labelled highly purified rat hsp 90 was characterized by 
high-performance size-exclusion chromatography as a 
peak with a 6.8 nm Stokes radius, which was shifted to 
more than 8.5 nm after preincubation in the presence of 
AS 232-266. However no shift was observed with un- 
transformed GR complexes (Fig. 3B), demonstrating 
that the epitope recognized by AS 232-266 in free hsp 
90 was not accessible in these complexes, which do con- 
tain hsp 90 as demonstrated by Western blot experiments 
[26]. This result is consistent with a possible involve- 
ment of this epitope in the binding of hsp 90 to GR. 
3.2. Both AS 232-266 and peptide 232-266 interfere 
with [3H]dexamethasone-GR complex formation 
When added to rat liver cytosol, AS 232-266, but not 
preimmune or unrelated sera, was able to lower [3H]dex- 
amethasone binding to GR in a dose-dependent manner 
(Fig. 4A). This phenomenon could be explained by the 
binding of AS 232-266 to ligand-free hsp 90-Gr com- 
Fig. 2. Western blot analysis of cytosolic mouse hsp 90. Following 
SDS-PAGE and electrotransfer to nitrocellulose filters, blots were 
revealed with monoclonal antibody AC 88 (lane 3), the pre-immune 
antiserum 232-266 (lane 4), a non-relevant antiserum (lane 5) and the 
immune antiserum AS 232-266 either crude (lane 6) or after immuno- 
globulin fractionation (lane 7). Control strips were also revealed with 
AS 232-266 preincubated with peptide 2322266 (lane 8) or with an 
unrelated peptide (lane 9). The positions of proteins size markers 
(kDa) are shown (lane 1). 
plexes, resulting in the masking of the GR ligand bind- 
ing domain. The hsp 90 epitope recognized by AS 232- 
266 and the GR binding site could be close enough to 
each other to result in mutually exclusive binding of AS 
232-266 and [3H]dexamethasone. This hypothesis is re- 
inforced by the observation that in the presence of AS 
232-266, performed [3H]dexamethasone-GR com- 
plexes dissociate with the same kinetics as in the pres- 
ence of an excess of unlabelled dexamethasone (data not 
shown). Interestingly peptide 232-266SAB conjugates, 
but not free SAB or conjugates with unrelated peptides, 
also appeared able to compete for [3H]dexamethasone 
binding to GR (Fig. 4B). This observation promted the 
hypothesis that peptide 232-266 could destabilize li- 
gand-free hsp 90-GR complexes, yielding a GR form 
with lowered ligand-binding ability. 
3.3. Dissociation of 7 nm hsp 90-Gr complexes in the 
presence of peptide 232-266 
When cytosolic GR were incubated overnight in the 
presence of 10 nM [3H]dexamethasone and 25 PM free 
peptide 232-266 only a 20-25% decrease in binding 
activity was observed, i.e. far less than with the corre- 
sponding peptide-BSA conjugate. However, when 
analyzed by high-performance size-exclusion chroma- 
Fig. 1. Amino acid sequence 232-266 from mouse [27], rat [30] and human [29] hsp 9Op and the corresponding sequence from chick hsp 90 [19]. 
Conserved residues are indicated by an asterisk. Dashes represent gaps resulting from alignment. 
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Fig. 3. Interaction of AS 232-266 with native hsp 90 and CR com- 
plexes. (A) Purified ‘251-labelled, rat liver hsp 90 samples (40 pg) were 
incubated overnight at 0°C in the presence or not of AS 232-266 (1:30 
final dilution) and loaded on a TSK G4000 SW column (0.75 x 30 cm). 
Elution was performed in buffer C (20 mM TES, pH 7.0, 1 mM 
EDTA, 200 mM NaCl) at a 0.5 ml min-’ flow rate, 0.25 ml fractions 
were collected and assayed for radioactivity. Arrows indicate elution 
volumes of Stokes radius markers: thyroglobuline (8.3 nm),p-galacto- 
sidase (6.9 nm) and aldolase (5.2 nm). (B) Rat liver cytosol samples 
were incubated with [‘Hldexamethasone 10 nM and in the presence 
or not of AS 232-266 (1:20 final dilution). Size-exclusion was per- 
formed in buffer C supplemented with 10 mM sodium molybdate. 
tography, [3H]dexamethasone-GR complexes appeared 
completely dissociated into the 5 nm form (Fig. 5). This 
result was obtained at 0°C and in the presence of so- 
dium molybdate, i.e. under conditions that stabilize the 
7 nm hsp 90 containing GR complexes. Therefore pep- 
tide 232-266 appears able to destabilize and dissociate 
hsp 90-GR complexes. 
4. DISCUSSION 
Two modes of binding of hsp 90 to steroid hormone 
receptors are currently evoked. Hydrophobic interac- 
tions could involve the ligand binding domain (LBD) of 
the receptors. Certain critical regions of this domain 
have been localized, specially in the case of GR [10-l 31. 
However it is now clear for the progesterone [ 16,181 and 
the estrogen receptor [17], and probably also for the GR 
[14,15], that hsp 90 bind to the LBD through interac- 
tions at multiple locations. The implication of putative 
leucine-zippers has been hypothesized on both the 
receptors and hsp 90 [34], which comprises highly hy- 
drophobic regions [35]. On the other hand polar interac- 
tions could also contribute to the hsp 90-receptor com- 
plex stability. A very polar, mainly basic, region of the 
receptor, encompassing the terminal part of the DNA 
binding domain (DBD) and the hinge region between 
the DBD and the LBD could be recognized by specific 
antibodies in transformed, (hsp 90-free) but not in un- 
transformed (hsp 90 containing) GR and PR complexes 
[36,37]. This region, which could be masked by hsp 90 
in the untransformed complexes, appeared essential for 
hsp 90 binding to the estrogen receptor [17], but not to 
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Fig. 4. Inhibition of GR steroid binding activity by AS 2322266 and 
peptide 232-266SAB conjugates. Rat liver cytosol samples (0.5 ml) 
were incubated overnight in the presence of [3H]dexamethasone and 
of (A) increasing amounts of fractionated AS 232-266 or unrelated 
antibodies and (B) increasing concentrations of peptide 232-266BSA 
conjugates or unrelated peptideeBSA conjugates. Specific binding is 
expressed as percent of a control incubated in the presence of [‘Hldex- 
amethasone alone. 
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Fig. 5. Effect of peptide 232-266 on the Stokes radius of untrans- 
formed GR. Rat liver cytosol samples were incubated overnight in the 
presence of 10 nM [3H]dexamethasone and in the presence or absence 
of 25 PM peptide 232-266, and analyzed by size-exclusion chromatog- 
raphy on a TSK G3000 column as described in Fig. 3. 
GR [38]. However, even if it is not essential, this region 
could nevertheless contribute to GR binding. Its coun- 
terpart on hsp 90 could be the polar region including 
peptide 232-266 [19]. Indirect arguments for the impli- 
cation of this very acidic region in hsp 90 binding to GR 
are the dissociation of hsp 90-GR complexes at pH 4.0, 
a value close to the pK of the Asp and Glu residues 
present in abundance in this region [39], and the fact 
that this region is absent in the bacterial hsp 90 equiva- 
lent, which does not bind steroid receptors [40]. Our 
data afford new and more direct evidence that the acidic 
domain of hsp 90 plays a role in the stabilization of hsp 
90-GR complexes. 
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